Hikma Pharmaceuticals PLC (LON:HIK) Receives GBX 2,068.75 Consensus Target Price from Brokerages

Hikma Pharmaceuticals PLC (LON:HIK – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the six research firms that are presently covering the company, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12-month target […]

Leave a Reply

Your email address will not be published.

Previous post JOANN (NASDAQ:JOANQ) and Hibbett (NASDAQ:HIBB) Financial Comparison
Next post Dada Nexus Limited (NASDAQ:DADA) Receives $4.85 Average Price Target from Analysts